Effect of Polyphenols on Absorption of Iron From Sodium Iron Chlorophyllin

NCT ID: NCT04849832

Last Updated: 2021-11-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-06-21

Study Completion Date

2021-07-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Polyphenols present in tea are known to inhibit the absorption of non heme iron. The inhibiting effect of tea on non-heme iron absorption is attributed to the flavonoids present in tea. It is well known that Ferrous sulfate is not absorbed well in the presence of polyphenols. We would like to evaluate the effect of polyphenols on the newly developed compound, sodium iron chlorophyllin (SIC), which mimics the heme iron structure. Comparisons of fractional absorption of SIC and Ferrous Sulfate in the presence of polyphenols can help identify the performance of the compounds as vehicles for iron delivery in the presence of iron absorption inhibitors.

In a single-blind randomized cross-over study using stable iron isotope technique, iron bioavailability from SIC delivered with an inhibitory matrix can therefore be determined when given along with black tea

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

New approaches to treat iron deficiency include developing novel iron compounds with possible iron absorption routes that increase iron bioavailability and reduce gastrointestinal side effects.

Sodium iron chlorophyllin (SIC) is a water-soluble semisynthetic chlorophyll derivative where the magnesium in the porphyrin ring has been substituted by iron. Given the porphyrin ring heme-like structure of SIC, it may be an alternative delivery route for iron, suitable also for vegetarians and vegans. Yet, there are few studies investigating the use of SIC for this purpose.

We recently completed the study entitled "Evaluation of iron bioavailability from iron chlorophyllin in young women using the iron stable isotopic method" based on previous in vitro and in vivo studies.. The study showed a 7% fractional iron absorption (FIA) from SIC when compared to the control compound, ferrous sulfate, which had a FIA of 30%, indicating a Relative Bioavailability of SIC of 20%. The study showed an inverse relationship between ferritin status and iron absorption from SIC in the study participants and an increase in the FIA in the presence of ascorbic acid. Both these findings lean towards the possibility that that the iron contributing to the FIA from SIC may be iron that was dissociated from the porphyrin ring of the chlorophyllin and entering the common non heme iron pool. This inverse relationship in ferritin and FIA is well known for ferrous sulfate. However, one cannot confirm the pathway taken up by SIC to deliver iron based on the previous study alone.

Polyphenols present in tea are known to inhibit the absorption of non heme iron.The inhibiting effect of tea on non-heme iron absorption is attributed to the flavonoids present in tea. There are several types of tea flavonoids: monomers (catechin), dimers (theaflavin), and polymers (thearubigin). Black tea contains 10% flavanols, 25% catechins, 20% theaflavins and 45% thearubigins. The mechanism of iron absorption inhibition by tea is by formation of a complex of the flavonoids with iron. It is mainly the galloyl group in these phenolic compounds that specifically binds iron. A cup of black tea, brewed with 2.5 g tea leaves contains about 200 mg tea flavonoids . Heme iron absorption has also been shown to be inhibited by the presence of polyphenols but unclear to what extent. Thus, comparisons of fractional absorption of SIC and Ferrous Sulfate in the presence of polyphenols can help identify the performance of the compounds as vehicles for iron delivery in the presence of iron absorption inhibitors.

In a single-blind randomized cross-over study using stable iron isotope technique, iron bioavailability from SIC delivered with an inhibitory matrix can therefore be determined when given along with black tea.

SIC has been produced at the HNL with a 50% incorporation of iron into the chlorophyll. Our protocol is based on a Unilever patent that is no longer active, with in-house adaptation. The SIC has a neutral taste and will be presented as a dark green liquid, being the solution of SIC in water.

If SIC, as hypothesized, behaves in a similar way to heme, then iron absorption inhibitors, such as the polyphenols, will not have an effect on the absorption of iron from SIC.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Iron-deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

The study will be a randomized, single centre cross over study where every participant will receive all the four interventions.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

There will be no masking as the ferrous sulfate solutions will be colourless compared to the green color solution of SIC

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SIC

4mg of Fe will be given as 102 mg of SIC as a solution

Group Type EXPERIMENTAL

SIC

Intervention Type DIETARY_SUPPLEMENT

Sodium Iron Chlorophyllin as prepared by the human nutrition laboratory, ETH Zurich

SIC + tea

4 mg of Fe will be given as 102 mg of SIC as a solution along with 200 ml of black tea

Group Type EXPERIMENTAL

SIC + tea

Intervention Type DIETARY_SUPPLEMENT

Sodium Iron Chlorophyllin as prepared by the human nutrition laboratory, ETH Zurich with 2g of tea brewed for 5 minutes

FeSO4

4 mg of Fe will be given as Ferrous sulfate solution

Group Type ACTIVE_COMPARATOR

FeSO4

Intervention Type DIETARY_SUPPLEMENT

Ferrous sulfate solution serves as a positive control - and whose absorption is well known.

FeSO4 + tea

4 mg of Fe will be given as Ferrous sulfate solution along with 200 ml of black tea

Group Type ACTIVE_COMPARATOR

FeSO4 + tea

Intervention Type DIETARY_SUPPLEMENT

Ferrous sulfate solution given with 2g of tea brewed for 5 minutes - expected iron absorption inhibition

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SIC

Sodium Iron Chlorophyllin as prepared by the human nutrition laboratory, ETH Zurich

Intervention Type DIETARY_SUPPLEMENT

SIC + tea

Sodium Iron Chlorophyllin as prepared by the human nutrition laboratory, ETH Zurich with 2g of tea brewed for 5 minutes

Intervention Type DIETARY_SUPPLEMENT

FeSO4

Ferrous sulfate solution serves as a positive control - and whose absorption is well known.

Intervention Type DIETARY_SUPPLEMENT

FeSO4 + tea

Ferrous sulfate solution given with 2g of tea brewed for 5 minutes - expected iron absorption inhibition

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* female aged between 18-45 y old;
* SF \<80 µg/L;
* BMI 18.5-24.9 kg/m2;
* weight \<70 kg;
* signed informed consent;
* able to communicate and comprehend English language.

Exclusion Criteria

* anemia (Hb \<12 g/dL);
* Inflammation (CRP \> 5 mg/L);
* chronic digestive, renal and/or metabolic disease;
* chronic medications (except for oral contraceptives);
* use of vitamin, mineral and pre- and/or probiotic supplements in the previous 2 weeks before study initiation and during the course of the study;
* blood transfusion, blood donation or significant blood loss over the past 4 months;
* difficulties with blood sampling;
* antibiotic treatment in the 4 weeks before study initiation;
* pregnancy (tested in serum at screening) or intention to become pregnant;
* lactation up to 6 weeks before study initiation;
* earlier participation in a study using stable isotopes or participation in any clinical study within the last 30 days;
* unable to comply with study protocol (e.g. not available on certain study appointment days or difficulties with blood withdrawal);
* inability to understand the information sheet and the informed consent form due to cognitive or language reasons;
* smoking;
* unwilling to use an effective method of contraception.
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Swiss Federal Institute of Technology

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jessica Farebrother, Dr.Sc

Role: PRINCIPAL_INVESTIGATOR

ETH Zurich

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

ETH Zürich, Laboratory of Human Nutrition

Zurich, Canton of Zurich, Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PolySIC

Identifier Type: -

Identifier Source: org_study_id